View Older Stories View More Recent Stories

May 15, 2023 07:27PM Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease
Mar 31, 2023 12:55AM Eisai: Additional Detailed Analyses from Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals
Dec 22, 2022 03:07AM Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging
Sep 28, 2022 07:00AM Eisai, Biogen (BIIB) Announce Lecanemab Confirmatory Phase 3 Clarity AD Study Met Primary Endpoint for Reduction of Early Alzheimer's Disease
Sep 27, 2022 07:30PM LECANEMAB CONFIRMATORY PHASE 3 CLARITY AD STUDY MET PRIMARY ENDPOINT, SHOWING HIGHLY STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN LARGE GLOBAL CLINICAL STUDY OF 1,795 PARTICIPANTS WITH E
Sep 10, 2022 05:20AM Eisai Presents Results of Post-Hoc Analysis of Eribulin Mesylate (HALAVEN®) at the European Society for Medical Oncology (ESMO) Congress 2022
Sep 6, 2022 08:08AM Eisai Presents New Data From its Oncology Portfolio and Pipeline at ESMO Congress 2022
Aug 23, 2022 09:00AM C2N and Eisai Collaborate to Build Awareness and Real-World Evidence for Blood-Based Assays for Cognitive Impairment in Clinical Practice Outside of Clinical Trial Settings
Aug 18, 2022 10:05AM Eisai Inc. Reinforces Commitment to Collaboration and Innovation to Support Patients and Communities Through New U.S. Headquarters
Aug 4, 2022 08:08AM BASEBALL LEGEND BERNIE WILLIAMS TEAMS UP WITH EISAI AND ADVOCACY PARTNERS TO LAUNCH ONE LIVER TO LOVE INITIATIVE TO HELP RAISE AWARENESS ABOUT LIVER CANCER AND THE IMPORTANCE OF LIVER HEALTH
Aug 3, 2022 07:32PM EISAI PRESENTS NEW FINDINGS ON LECANEMAB'S INVESTIGATIONAL SUBCUTANEOUS FORMULATION AND MODELING SIMULATION OF APOE4 GENOTYPE ON ARIA-E INCIDENCE AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENC
Jul 5, 2022 07:30PM THE U.S. FDA ACCEPTS AND GRANTS PRIORITY REVIEW FOR EISAI'S BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER'S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY
Jun 5, 2022 09:00AM Eisai Presents New Findings for Antibody Drug Conjugate Farletuzumab Ecteribulin at 2022 ASCO Annual Meeting
May 27, 2022 08:08AM Eisai Contributes to the Science of Cancer Medicine at ASCO 2022
Mar 31, 2022 08:00AM EISAI TO PRESENT DATA ON NEUROLOGY PORTFOLIO IN THE AREAS OF ALZHEIMER'S DISEASE, SLEEP AND EPILEPSY AT THE 74th AMERICAN ACADEMY OF NEUROLOGY® (AAN) ANNUAL MEETING
Mar 30, 2022 07:57AM MEAGAN GOOD SHARES HER SCARE WITH UTERINE CANCER TO ENCOURAGE PEOPLE TO SPOT THE EARLY SIGNS OF ENDOMETRIAL CANCER AS PART OF EISAI AND ADVOCACY PARTNERS' SPOT HER® CAMPAIGN
Mar 10, 2022 06:30PM Eisai To Present New Lecanemab Data Exploring Distinct Mechanism of Action and Clinical Outcomes, Disease State Symposium, and Other Pipeline Assets at the AD/PD™ 2022 Annual Meeting
Mar 3, 2022 06:30PM EISAI INITIATES SUBMISSION OF APPLICATION DATA UNDER THE PRIOR ASSESSMENT CONSULTATION SYSTEM IN JAPAN WITH THE AIM OF OBTAINING EARLY APPROVAL FOR INVESTIGATIONAL ANTI-AMYLOID BETA PROTOFIBRIL ANTIBO
Jan 24, 2022 08:05AM EISAI INC. ANNOUNCES THE APPOINTMENT OF TRICIA BROOKS AS VICE PRESIDENT & HEAD OF OFFICE, GOVERNMENT AFFAIRS AND POLICY
Jan 14, 2022 08:08AM Eisai to Present Research at the 2022 ASCO Gastrointestinal Cancers Symposium in Multiple Tumor Types from its Robust Oncology Portfolio
Dec 23, 2021 06:30PM INVESTIGATIONAL ALZHEIMER'S DISEASE THERAPY LECANEMAB GRANTED FDA FAST TRACK DESIGNATION
Dec 7, 2021 11:36AM Eisai Presents Its Largest Real-World Study Of Anti-Epileptic Drug FYCOMPA® (perampanel) Across Patient Types At The 2021 American Epilepsy Society (AES) Annual Meeting
Dec 7, 2021 08:35AM #ThisIsMBC "fearLESS" Campaign Portrays Powerful Portraits of People Living fearLESSly with Metastatic Breast Cancer Through Friendship, Community and Making Each Day Count
Dec 7, 2021 08:00AM Eisai Presents Final Results Of Phase IV Elevate Study Of Anti-Epileptic Drug FYCOMPA® (perampanel) At The American Epilepsy Society (AES) 2021 Annual Meeting
Dec 1, 2021 03:15PM Eisai To Present Real-World Evidence And Convulsive Seizure Freedom Data Evaluating FYCOMPA® (perampanel) Across Patient Types At 75th American Epilepsy Society (AES) Annual Meeting
Nov 11, 2021 12:00PM Introduction of First-Of-A-Kind Plasma-Based Biomarker Screening To Facilitate Identification Of Subjects For Phase 3 Ahead 3-45 Trial Presented At Clinical Trials On Alzheimer's Disease (CTAD) Confer
Nov 11, 2021 11:20AM Eisai Presents New Analysis Of Lecanemab Clinical Efficacy Results From Phase 2b Study At Clinical Trials On Alzheimer's Disease (CTAD) Conference
Nov 10, 2021 02:57PM Eisai Presents Late-Breaker Updates On Lecanemab Clinical, Biomarker And Safety Data From Phase 2b Study Core And Open-Label Extension Across Five Years At Clinical Trials On Alzheimer's Disease (CTAD
Sep 27, 2021 07:30PM Eisai Initiates Rolling Submission To The U.S. FDA For Biologics License Application Of Lecanemab (BAN2401) For Early Alzheimer's Disease Under The Accelerated Approval Pathway
Sep 13, 2021 08:08AM Data at ESMO Congress 2021 Underscore Depth of Eisai's Oncology Pipeline and Commitment to Cancer Care
Aug 30, 2021 07:55AM Eisai Announces New Executive Leadership Team at H3 Biomedicine
Aug 5, 2021 07:55AM Eisai Inc. Announces the Appointment of Dr. Janna Hutz as President of the Eisai Center for Genetics Guided Dementia Discovery
Jul 29, 2021 04:30PM Late-Breaking AAIC Presentation Explores Potential Clinical Effects Of Lecanemab (BAN2401)
Jun 28, 2021 07:55AM Eisai Inc. Announces the Appointment of Dr. Andree Amelsberg as Vice President, U.S. Medical Affairs, Oncology Business Group
Jun 23, 2021 04:07PM Eisai, Biogen (BIIB) Announce U.S. FDA Grants Breakthrough Therapy Designation For Lecanemab (BAN2401), An Anti-Amyloid Beta Protofibril Antibody For The Treatment Of Alzheimer's Disease
Jun 23, 2021 04:06PM Eisai And Biogen Inc. Announce U.S. FDA Grants Breakthrough Therapy Designation For Lecanemab (BAN2401), An Anti-Amyloid Beta Protofibril Antibody For The Treatment Of Alzheimer's Disease
Jun 9, 2021 08:04AM Eisai to Present Latest DAYVIGO® (lemborexant) CIV Data at 35th Annual Virtual SLEEP 2021 Meeting
May 24, 2021 08:45AM Hackensack Meridian Health and Eisai Inc. Join Forces to Support the Expansion of Alzheimer's Disease Detection and Services for Patients
May 18, 2021 08:34AM Eisai Announces Real-World Data on the Effectiveness of HALAVEN® (eribulin mesylate) for the Treatment of Patients with Metastatic Breast Cancer (mBC) Published in Advances in Therapy
May 17, 2021 08:08AM Eisai Data at ASCO 2021 Highlight Breadth of Oncology Portfolio Across Various Tumor Types
Apr 29, 2021 08:08AM Eisai Announces Publication of Post Hoc Analysis Data of LENVIMA® (lenvatinib) from Phase 3 SELECT Trial in Certain Patients with Differentiated Thyroid Cancer in the European Journal of Cancer
Apr 16, 2021 11:53AM Eisai Presents Breadth of Data Across Neurology Portfolio, Including Alzheimer's Disease, Insomnia and Epilepsy
Mar 31, 2021 08:08AM Eisai And Advocacy Leaders Team Up To Launch Spot Her - An Initiative That Empowers Women To Help Spot The Signs Of Endometrial Cancer
Mar 10, 2021 08:08AM Eisai to Present Investigational Data from Oncology Pipeline at the Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women's Cancer
Mar 5, 2021 08:52AM Eisai Alzheimer's Disease Pipeline Research to be Presented at Virtual AD/PD™ 2021, Including Lecanemab (BAN2401) Data
Feb 2, 2021 02:39PM Eisai and BioLabs Partner to Create the Eisai Innovation Center BioLabs
Jan 27, 2021 08:08AM Eisai to Present Investigational Data on LENVIMA® (lenvatinib) Based Combination Therapies in Renal Cell Carcinoma at the 2021 Genitourinary Cancers Symposium
Jan 20, 2021 07:55AM Dr. Richard Woodman Appointed Chief Clinical Officer of the Oncology Business Group at Eisai Inc.
Jan 11, 2021 08:08AM Eisai to Present Data on LENVIMA® (lenvatinib) Monotherapy and in Combination with KEYTRUDA® (pembrolizumab) in Multiple Cancer Types at the 2021 Gastrointestinal Cancers Symposium
Dec 8, 2020 07:38AM #ThisIsMBC Perseverance Campaign from Eisai and METAvivor Captures the Joys, Difficulties and Realities Faced by People Living with Metastatic Breast Cancer
View More Recent Stories View Older Stories